{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:7065"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:7065","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Characterising the PEPITEM pathway in patients with atherosclerosis","abstract":"Atherosclerosis is an asymptomatic disease which is regarded as one of the most fatal diseases. However, the mechanism of the immune response is not well understood. There is accumulated evidence supporting the idea that inflammatory response initiates the disease. A new novel peptide has been discovered in our lab which down-regulates T cell recruitment during inflammation called PEPITEM (Peptide Inhibitor of Trans Endothelial Migration). We are interested in testing the action of PEPITEM on PBL isolated from atherosclerosis patients. We first demonstrated that PEPITEM did not affect the levels of adhesion of PBL from either diseased or healthy donors. Interestingly however, we did observe that PBL isolated from atherosclerosis patients adhere more readily than those isolated from healthy control subjects. Therefore, we studied the surface expression of certain adhesion molecules and chemokine receptors on the PBL of atherosclerosis patients. We found significantly higher surface expression of Beta-receptor family (Beta-1 and Beta-2) and PSGL-1 receptors in some PBL subsets in atherosclerosis patients. In addition, we looked at the effect of PEPITEM and adiponectin (AQ) treatment on the migration of PBL and we revealed for the first time based on our knowledge that there was no effect of treatment on PBL isolated from atherosclerosis patients. These observations will contribute to understanding the potential therapeutic applications of PEPITEM on atherosclerosis.","abstract_html":"Atherosclerosis is an asymptomatic disease which is regarded as one of the most fatal diseases. However, the mechanism of the immune response is not well understood. There is accumulated evidence supporting the idea that inflammatory response initiates the disease. A new novel peptide has been discovered in our lab which down-regulates T cell recruitment during inflammation called PEPITEM (Peptide Inhibitor of Trans Endothelial Migration). We are interested in testing the action of PEPITEM on PBL isolated from atherosclerosis patients. We first demonstrated that PEPITEM did not affect the levels of adhesion of PBL from either diseased or healthy donors. Interestingly however, we did observe that PBL isolated from atherosclerosis patients adhere more readily than those isolated from healthy control subjects. Therefore, we studied the surface expression of certain adhesion molecules and chemokine receptors on the PBL of atherosclerosis patients. We found significantly higher surface expression of Beta-receptor family (Beta-1 and Beta-2) and PSGL-1 receptors in some PBL subsets in atherosclerosis patients. In addition, we looked at the effect of PEPITEM and adiponectin (AQ) treatment on the migration of PBL and we revealed for the first time based on our knowledge that there was no effect of treatment on PBL isolated from atherosclerosis patients. These observations will contribute to understanding the potential therapeutic applications of PEPITEM on atherosclerosis.","abstract_has_math":false,"creators":["Alassiri, Mohammed"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-12","date_published":"2016-12","updated_at":"2026-11-19T09:29:11Z","subjects":["QR180 Immunology","RC Internal medicine"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/7065/1/Alassiri16PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A7065","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Alassiri, Mohammed"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2016-12"]},{"key":"dc:date.issued","label":"Date","values":["2016-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["School of Medicine, Centre of Cardiovascular Science"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/7065/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology","RC Internal medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/7065/1/Alassiri16PhD.pdf","http://etheses.bham.ac.uk//id/eprint/7065/2/Decl_IS_Alassiri16PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Atherosclerosis is an asymptomatic disease which is regarded as one of the most fatal diseases. However, the mechanism of the immune response is not well understood. There is accumulated evidence supporting the idea that inflammatory response initiates the disease. A new novel peptide has been discovered in our lab which down-regulates T cell recruitment during inflammation called PEPITEM (Peptide Inhibitor of Trans Endothelial Migration). We are interested in testing the action of PEPITEM on PBL isolated from atherosclerosis patients. We first demonstrated that PEPITEM did not affect the levels of adhesion of PBL from either diseased or healthy donors. Interestingly however, we did observe that PBL isolated from atherosclerosis patients adhere more readily than those isolated from healthy control subjects. Therefore, we studied the surface expression of certain adhesion molecules and chemokine receptors on the PBL of atherosclerosis patients. We found significantly higher surface expression of Beta-receptor family (Beta-1 and Beta-2) and PSGL-1 receptors in some PBL subsets in atherosclerosis patients. In addition, we looked at the effect of PEPITEM and adiponectin (AQ) treatment on the migration of PBL and we revealed for the first time based on our knowledge that there was no effect of treatment on PBL isolated from atherosclerosis patients. These observations will contribute to understanding the potential therapeutic applications of PEPITEM on atherosclerosis."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Characterising the PEPITEM pathway in patients with atherosclerosis"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Alassiri, Mohammed"],"dc:date":["2016-12"],"dc:date.issued":["2016-12"],"dc:description.abstract":["Atherosclerosis is an asymptomatic disease which is regarded as one of the most fatal diseases. However, the mechanism of the immune response is not well understood. There is accumulated evidence supporting the idea that inflammatory response initiates the disease. A new novel peptide has been discovered in our lab which down-regulates T cell recruitment during inflammation called PEPITEM (Peptide Inhibitor of Trans Endothelial Migration). We are interested in testing the action of PEPITEM on PBL isolated from atherosclerosis patients. We first demonstrated that PEPITEM did not affect the levels of adhesion of PBL from either diseased or healthy donors. Interestingly however, we did observe that PBL isolated from atherosclerosis patients adhere more readily than those isolated from healthy control subjects. Therefore, we studied the surface expression of certain adhesion molecules and chemokine receptors on the PBL of atherosclerosis patients. We found significantly higher surface expression of Beta-receptor family (Beta-1 and Beta-2) and PSGL-1 receptors in some PBL subsets in atherosclerosis patients. In addition, we looked at the effect of PEPITEM and adiponectin (AQ) treatment on the migration of PBL and we revealed for the first time based on our knowledge that there was no effect of treatment on PBL isolated from atherosclerosis patients. These observations will contribute to understanding the potential therapeutic applications of PEPITEM on atherosclerosis."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/7065/1/Alassiri16PhD.pdf","http://etheses.bham.ac.uk//id/eprint/7065/2/Decl_IS_Alassiri16PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["School of Medicine, Centre of Cardiovascular Science"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/7065/"],"dc:subject":["QR180 Immunology","RC Internal medicine"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Characterising the PEPITEM pathway in patients with atherosclerosis"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:29:11Z"}